Genmab Announces RG1507 Update

Summary:  Roche to discontinue RG1507 program.                                  

Copenhagen, Denmark; December 4, 2009 - Genmab A/S (OMX: GEN) announced today   
that Roche has informed Genmab that it will discontinue development of RG1507, a
monoclonal antibody directed against the insulin-like growth factor-1 receptor  
(IGF-1R).  The decision was due to the available clinical data, the large number
of molecules targeting the same pathway that are presently in development and   
the prioritization of the Roche portfolio.  The decision was not as a result of 
safety concerns.                                                                

RG1507 is a fully human antibody created by Genmab under its collaboration with 
Roche.  RG1507 was in Phase II development for multiple indications including   
sarcoma and non small cell lung cancer.                                         

“Despite this setback, Roche and Genmab continue to have a strong working       
relationship, with one shared aim of developing and providing novel efficacious 
agents to the patients that need them,” said Lisa N. Drakeman, Ph.D., Chief     
Executive Officer of Genmab.                                                    


About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for the potential treatment of cancer.        
Genmab's world class discovery and development teams are using cutting-edge     
technology to create and develop products to address unmet medical needs.  Our  
primary goal is to improve the lives of patients who are in urgent need of new  
treatment options.  For more information on Genmab's products and technology,   
visit www.genmab.com.                                                           

This Stock Exchange Release contains forward looking statements. The words      
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions  
identify forward looking statements. Actual results or performance may differ   
materially from any future results or performance expressed or implied by such  
statements. The important factors that could cause our actual results or        
performance to differ materially include, among others, risks associated with   
product discovery and development, uncertainties related to the outcome and     
conduct of clinical trials including unforeseen safety issues, uncertainties    
related to product manufacturing, the lack of market acceptance of our products,
our inability to manage growth, the competitive environment in relation to our  
business area and markets, our inability to attract and retain suitably         
qualified personnel, the unenforceability or lack of protection of our patents  
and proprietary rights, our relationships with affiliated entities, changes and 
developments in technology which may render our products obsolete, and other    
factors. For a further discussion of these risks, please refer to the section   
“Risk Management” in Genmab's Annual Report, which is available on              
www.genmab.com.  Genmab does not undertake any obligation to update or revise   
forward looking statements in this Stock Exchange Release nor to confirm such   
statements in relation to actual results, unless required by law.               

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM);
HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM);  
HuMax-TF(TM); HuMax-Her2(TM); HuMax-VEGF(TM) and UniBody(R) are all trademarks  
of Genmab A/S. Arzerra(TM) is a trademark of GlaxoSmithKline.                   

Contact: Helle Husted, Vice President, Investor Relations, T: +45 33 44 77 30,  
M: +45 25 27 47 13, E: h.husted@genmab.com                                      
                                                                                
Stock Exchange Release no. 47/2009                                              

###